Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years with informed consent~* Diagnosis of rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria)~* Disease duration \> 6 weeks~* Swollen joint (SJC)≥4 and tender joint count(TJC)≥4~* ESR \>28 mm/hr or C-reactive protein \> 1.5 ULN~* Positive RF or anti-CCP antibody on screening~* Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA~* No evidence of active or latent or inadequately treated Mycobacterium tuberculosis infection~Exclusion Criteria:~* Pregnant, lactating or further fertility requirements~* Previously received any biologic agents.~* Recently (\<12 weeks) received methotrexate, leflunomide, salazosulfapyridine, azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii.~* Active or chronic infection, including HIV, HCV, HBV, tuberculosis.~* History of any other rheumatic autoimmune disease~* History of any lymphoproliferative disorder~* Malignancy or history of malignancy.~* Abnormal laboratory tests, including: Hemoglobin \<8.5 g/dL, White blood cell count \<3.5 x 109/L, Platelet count \<100 x 109/L, AST/ALT \>1.5 ULN, and serum creatine \> 1.5 mg/dL.~* Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MTX (Type: PLACEBO_COMPARATOR): Treated with oral methotrexate and two placebos.
- Tripterygium Wilfordii (Type: PLACEBO_COMPARATOR): Treated with oral Tripterygium Wilfordii and two placebos.
- Yisaipu + MTX (Type: ACTIVE_COMPARATOR): Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
- Yisaipu + Tripterygium Wilfordii (Type: EXPERIMENTAL): Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).